sees q2 adjusted earnings per share $0.54 to $00.60 excluding items.
sees fy adjusted earnings per share $2.07 to $2-2.27.
q1 adjusted earnings per share $0.54.
sees fy sales $4.9 billion to $5.3 billion.
qtrly net sales $1.2 billion, up 5% on a constant currency basis.
q1 sales rose 5 percent to $5.4 billion.
q1 sales rose 7 percent to $213 million.
q1 sales rose 4 percent to $792 million.
q1 sales $196 million versus refinitiv ibes estimate of $195.7 million.
sees fy 2021 diluted net income per share to be between 630 and 635 million.
sees underlying tavr sales growth in the range of 15% to 20% in 2021.
compname reports third quarter 2021 results and announces third quarter and full year 2021 results.
qtrly u.s. sales of $3.3 billion.
reaffirms 2021 sales guidance of $80 million.
sees surgical structural heart market to grow in mid-single digits through 2026.
q1 earnings per share $0.01.
